Retatrutide 30mg + GHK-Cu 50mg

Retatrutide is an investigational GIP/GLP-1/glucagon triple-receptor agonist, while GHK-Cu is an investigational copper-binding peptide. Retatrutide is being studied for effects on body weight, appetite regulation and glucose metabolism, while GHK-Cu research focuses on tissue-remodelling, collagen and skin-related pathways.

Research areas include: weight-management and metabolic research, appetite and glucose regulation, collagen production, tissue repair, skin regeneration and cellular signalling. The combined Retatrutide + GHK-Cu formulation itself has not been established in clinical trials, so the individual research findings should not be interpreted as proven benefits of the combination.

Important: Both compounds are investigational and are not approved for general human use. This product is provided for research purposes only and is not intended to diagnose, treat, cure or prevent any disease or medical condition.

The Certificate of Analysis for lot GX-2026 confirms an HPLC purity of 99%+ and identity confirmed by mass spectrometry.

The Safety Data Sheet describes handling, storage and disposal information for this research compound. Always follow standard laboratory safety practice.